Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media.

Umland TC, Schultz LW, MacDonald U, Beanan JM, Olson R, Russo TA.

MBio. 2012 Aug 31;3(4). pii: e00113-12. doi: 10.1128/mBio.00113-12. Print 2012.

2.

Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology.

Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA.

Infect Immun. 2008 Aug;76(8):3577-86. doi: 10.1128/IAI.00269-08. Epub 2008 Jun 9.

3.

Genome-wide identification of Acinetobacter baumannii genes necessary for persistence in the lung.

Wang N, Ozer EA, Mandel MJ, Hauser AR.

MBio. 2014 Jun 3;5(3):e01163-14. doi: 10.1128/mBio.01163-14.

4.

The Response Regulator BfmR Is a Potential Drug Target for Acinetobacter baumannii.

Russo TA, Manohar A, Beanan JM, Olson R, MacDonald U, Graham J, Umland TC.

mSphere. 2016 May 11;1(3). pii: e00082-16. doi: 10.1128/mSphere.00082-16. eCollection 2016 May-Jun.

5.

Fluorescence High-Throughput Screening for Inhibitors of TonB Action.

Nairn BL, Eliasson OS, Hyder DR, Long NJ, Majumdar A, Chakravorty S, McDonald P, Roy A, Newton SM, Klebba PE.

J Bacteriol. 2017 Apr 25;199(10). pii: e00889-16. doi: 10.1128/JB.00889-16. Print 2017 May 15.

PMID:
28242720
6.

Joint Transcriptional Control of Virulence and Resistance to Antibiotic and Environmental Stress in Acinetobacter baumannii.

Gebhardt MJ, Gallagher LA, Jacobson RK, Usacheva EA, Peterson LR, Zurawski DV, Shuman HA.

MBio. 2015 Nov 10;6(6):e01660-15. doi: 10.1128/mBio.01660-15.

7.

New Mouse Model for Chronic Infections by Gram-Negative Bacteria Enabling the Study of Anti-Infective Efficacy and Host-Microbe Interactions.

Pletzer D, Mansour SC, Wuerth K, Rahanjam N, Hancock RE.

MBio. 2017 Feb 28;8(1). pii: e00140-17. doi: 10.1128/mBio.00140-17.

8.

Acinetobacter baumannii Is Dependent on the Type II Secretion System and Its Substrate LipA for Lipid Utilization and In Vivo Fitness.

Johnson TL, Waack U, Smith S, Mobley H, Sandkvist M.

J Bacteriol. 2015 Dec 14;198(4):711-9. doi: 10.1128/JB.00622-15.

9.

Structure of shikimate kinase, an in vivo essential metabolic enzyme in the nosocomial pathogen Acinetobacter baumannii, in complex with shikimate.

Sutton KA, Breen J, MacDonald U, Beanan JM, Olson R, Russo TA, Schultz LW, Umland TC.

Acta Crystallogr D Biol Crystallogr. 2015 Aug;71(Pt 8):1736-44. doi: 10.1107/S139900471501189X. Epub 2015 Jul 31.

PMID:
26249354
10.

The secretome of Acinetobacter baumannii ATCC 17978 type II secretion system reveals a novel plasmid encoded phospholipase that could be implicated in lung colonization.

Elhosseiny NM, El-Tayeb OM, Yassin AS, Lory S, Attia AS.

Int J Med Microbiol. 2016 Dec;306(8):633-641. doi: 10.1016/j.ijmm.2016.09.006. Epub 2016 Oct 1.

PMID:
27713027
11.

AB5075, a Highly Virulent Isolate of Acinetobacter baumannii, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments.

Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y, Owen MT, Hallock JD, Kwak YI, Summers A, Li CZ, Rasko DA, Penwell WF, Honnold CL, Wise MC, Waterman PE, Lesho EP, Stewart RL, Actis LA, Palys TJ, Craft DW, Zurawski DV.

MBio. 2014 May 27;5(3):e01076-14. doi: 10.1128/mBio.01076-14.

12.

Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii.

Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, Pohl J, Lesho EP, Weiss DS.

MBio. 2013 May 21;4(3):e00021-13. doi: 10.1128/mBio.00021-13.

13.

[Distribution of blaOXA genes in Acinetobacter baumannii strains: a multicenter study].

Ciftci IH, Aşık G, Karakeçe E, Oksüz L, Yağcı S, Sesli Çetin E, Ozdemir M, Atasoy AR, Koçoğlu E, Gül M, Kurtoğlu MG, Köksal Çakırlar F, Seyrek A, Berktaş M, Gültepe B, Ayyildiz A.

Mikrobiyol Bul. 2013 Oct;47(4):592-602. Turkish.

14.
15.

Clinically Relevant Growth Conditions Alter Acinetobacter baumannii Antibiotic Susceptibility and Promote Identification of Novel Antibacterial Agents.

Colquhoun JM, Wozniak RA, Dunman PM.

PLoS One. 2015 Nov 11;10(11):e0143033. doi: 10.1371/journal.pone.0143033. eCollection 2015.

16.

Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae.

Carlson-Banning KM, Chou A, Liu Z, Hamill RJ, Song Y, Zechiedrich L.

PLoS One. 2013 Jul 23;8(7):e69646. doi: 10.1371/journal.pone.0069646. Print 2013.

17.

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249.

PMID:
18684704
18.

Oligonucleotide array-based identification of species in the Acinetobacter calcoaceticus-A. baumannii complex in isolates from blood cultures and antimicrobial susceptibility testing of the isolates.

Ko WC, Lee NY, Su SC, Dijkshoorn L, Vaneechoutte M, Wang LR, Yan JJ, Chang TC.

J Clin Microbiol. 2008 Jun;46(6):2052-9. doi: 10.1128/JCM.00014-08. Epub 2008 Apr 2.

19.
20.

In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.

Vidaillac C, Benichou L, Duval RE.

Antimicrob Agents Chemother. 2012 Sep;56(9):4856-61. doi: 10.1128/AAC.05996-11. Epub 2012 Jul 2.

Supplemental Content

Support Center